P95 is a full-service provider for epidemiological and clinical studies. For epidemiological studies, P95 finds, collects, analyses, and reports epidemiological data to assist public health agencies, research organizations and pharmaceutical companies in improving people’s access to safe and effective vaccines. For clinical studies, P95 assists its clients and partners for end-to-end study activities, from site identification, feasibility and selection to study implementation and reporting. P95’s main area of expertise is vaccine development and infectious diseases, and this knowledge is applied when providing scientific and logistical support in the implementation of related epidemiological and clinical trials, as well as when providing consultancy in pharmaco-epidemiology, pharmacovigilance, medical writing, statistics, etc.
P95 was founded by CEO Thomas Verstraeten in 2011. Since then, the company has been growing rapidly and counts now more than 100 employees. P95 has its headquarters in Belgium. Since 2021 we also have a hub in the Netherlands (Rotterdam, The Netherlands), in Latin-America (Bogota, Colombia), and in Southeast Asia (Bangkok) to reach global coverage.
P95 employees work in a hybrid/remote setting in several countries including Belgium, the Netherlands, Spain, Greece, France, Germany, Portugal, Denmark, Finland, Czech Republic, Slovakia, Croatia, Poland, UK, USA, Colombia, Brazil, Mexico and Bangkok. Through its global presence on five continents, P95 is able to support studies in any geographical area.
P95 encompasses a team of epidemiologists, medical doctors, data scientists, medical writers, IT engineers, pharmacovigilance specialists, administrative staff, project/study operation managers, project support officers and CRAs.
